Adriamycin

Doxorubicin

Method of action: Antitumour

Treatment option: Hodgkin Disease, Bronchogenic Carcinoma, Carcinoma, Gastric Carcinoma, Leukemia, Lymphoma, Metastatic Breast Cancer, Neuroblastoma, Childhood Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adriamycin

Property	Description
Active ingredient	Doxorubicin hydrochloride
Form	Solution for Injection or Powder for Solution
Pharmacological class	Anthracycline Antineoplastic Agent
Common use	Systemic therapy for malignancies
Origin	Natural product (derived from Streptomyces peucetius var. caesius)

What is Adriamycin and What Type of Medicine is It?

Adriamycin is the well-known trade name for the powerful antineoplastic medication whose active substance is Doxorubicin (Doxorubicin hydrochloride). This medicine belongs to the Anthracycline class of chemotherapeutic agents, which are highly specialized, prescription-only drugs designated for systemic therapy against various malignancies. Doxorubicin is a frequently used antineoplastic agent with broad clinical application. This classification means the drug has established utility across diverse cancer protocols. Unlike standard antibiotics used to treat common infections, Doxorubicin is classified as a cytotoxic antibiotic because its fundamental purpose is to exert a cell-killing effect, providing decisive antitumor activity by targeting and halting the uncontrolled growth of cancer cells, a property clinically recognized for its effectiveness against solid tumors and hematologic cancers.

Composition, Origin, and Available Forms

The composition of Adriamycin is based on the single active substance Doxorubicin, derived from a natural product originally isolated from the fermentation culture of the bacterium Streptomyces peucetius var. caesius. This origin defines its classification as a natural-source anthracycline antibiotic. Doxorubicin is also available under other brand names, such as Doxil or Caelyx, which feature a specialized liposomal formulation that encapsulates the active ingredient to potentially alter its distribution in the body, representing a differentiating feature from the standard Adriamycin formulation. For clinical administration, Doxorubicin is typically supplied as a sterile Solution for Injection or as a Powder for Solution that requires reconstitution with an aqueous solution before use. The primary mode of delivery is the Intravenous route to ensure the active substance reaches cancerous tissue throughout the body, though the Intravesical route is sometimes utilized for specific localized applications.

Basic Principle of Action

The core principle behind Doxorubicin's action is its ability to directly damage the genetic material of rapidly dividing cells, forcing them to die. This effect is achieved because the drug acts as an intercalating agent that inserts itself into the DNA structure, physically disrupting the cell's ability to repair and copy its genetic information. Furthermore, it functions as a potent Topoisomerase II inhibitor, neutralizing a key enzyme necessary for the proliferation of malignant cells. This combined cytotoxic action dictates its general therapeutic purpose: to provide aggressive intervention to control and destroy proliferating tumors.

Regulatory References

What side effects are possible with Adriamycin?

Possible side effects and safety information

The safety profile of Adriamycin (Doxorubicin) is characterized by specific, often severe, adverse reactions documented in official regulatory labeling, including the FDA and EMA prescribing information. These effects are formally classified by frequency and the organ system affected.

Serious Adverse Reactions and Systemic Safety Patterns

The primary safety concern is Cardiotoxicity, which can lead to Chronic Cardiomyopathy and irreversible Congestive Heart Failure (CHF). The risk of this serious reaction is directly related to the cumulative lifetime dose administered. Another serious, dose-limiting effect is Myelosuppression (bone marrow suppression), which is classified as Very Common and includes conditions like Neutropenia, Leukopenia, and Anemia. A serious, though Uncommon, risk is the development of a secondary malignancy, specifically Acute Myeloid Leukemia (AML).

Common Effects and System-Organ Classes

Adverse effects are categorized by the systems involved:

Blood and Lymphatic System Disorders: Includes Myelosuppression (Very Common).
Gastrointestinal Disorders: Nausea, Vomiting, and Mucositis/Stomatitis (inflammation of the mouth/gut lining) are listed as Very Common.
Skin and Subcutaneous Tissue Disorders: Alopecia (hair loss) is nearly universal (Very Common) and typically reversible upon cessation of therapy.

Safety Restrictions and Special Populations

Official labeling mandates safety constraints based on a patient’s condition and total exposure:

Exposure Limit: A Maximum Lifetime Cumulative Dose limit must be observed to manage the risk of irreversible cardiotoxicity.
Hepatic Impairment: Dose reduction is required in patients with impaired liver function based on bilirubin levels. Severe hepatic impairment is listed as a contraindication.
Time-Related Pattern: Mucositis commonly develops approximately 3 to 10 days following administration.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the Doxorubicin (Adriamycin) overdose profile by the potentiation of severe, acute toxic manifestations and the risk of delayed, fatal complications.

Documented Overdose Manifestations and Outcomes

Overexposure may lead to severe acute toxicities, including life-threatening severe myelosuppression (bone marrow suppression) and severe gastrointestinal mucositis (inflammation of the mucous lining). The most critical long-term hazard documented is the increase in risk for delayed, irreversible myocardial toxicity that may result in congestive heart failure months or years after the overexposure event. Acute signs may include transient ECG abnormalities.

Required Emergency Actions

In the event of confirmed or suspected overdose, or if acute signs of a severe reaction occur (such as difficulty breathing, collapse, or seizure), official guidance states that immediate medical attention must be sought. For patients receiving intravenous administration, the infusion must be discontinued immediately if extravasation (drug leakage outside the vein) is suspected, as this can lead to severe local tissue necrosis. Regulatory documents confirm that no specific antidote is known for Doxorubicin overexposure, meaning management relies strictly on symptomatic and supportive treatment to manage the resulting severe toxicities.

Therapeutic Uses of Adriamycin

What Adriamycin Treats: Main Uses and Benefits

The primary therapeutic role of Adriamycin (Doxorubicin) is to help manage malignancies across domains where additional symptomatic support is needed. It is applied in addressing symptom clusters that may become intense or disruptive, especially in contexts involving advanced disease. Doxorubicin is considered relevant for use across a wide array of cancers, confirming its broad therapeutic role.

Systemic Treatment of Solid Tumors and Sarcomas

Adriamycin is commonly used as a foundational therapy for conditions presenting with systemic or localized discomfort, including breast cancer, ovarian carcinoma, and various sarcomas (cancers of the bone and soft tissue). This use may assist with managing symptom intensity, and supports the overall effort in contexts where functional stability becomes affected.

Management of Leukemias and Lymphomas

This medication is commonly used in addressing hematologic malignancies, playing a role in managing protocols for both Acute Lymphoblastic Leukemia (ALL) and Acute Myeloblastic Leukemia (AML). Furthermore, it is relevant for easing symptoms associated with Hodgkin Lymphoma and Non-Hodgkin Lymphoma. By addressing these conditions involving episodic or fluctuating manifestations, it helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Tumor-Related Distress (Used in advanced stages to shrink tumors, which supports the patient by easing functional strain and discomfort.)

Regulatory References

Doxorubicin Hydrochloride - NCI Therapeutic Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Adriamycin? (Doxorubicin)

Official regulatory documents strictly define the patient populations eligible to receive Adriamycin, based primarily on existing cardiac health, organ function, and prior treatment history.

Contraindications and Non-Eligibility

Adriamycin is contraindicated (must not be used) in patients presenting with several specific conditions, including severe myocardial insufficiency, recent myocardial infarction, severe persistent drug-induced myelosuppression, and severe hepatic impairment. Furthermore, patients who have reached the maximum lifetime cumulative dose of doxorubicin or related anthracyclines are absolutely ineligible for further use. Use is also contraindicated during pregnancy and lactation.

Restricted and Conditional Eligibility

Regulatory agencies impose restrictions based on organ function and age. Patients with mild to moderate hepatic impairment or severe renal insufficiency are only conditionally eligible and must receive a formal dosage reduction. Pediatric patients are eligible but are subject to lower cumulative maximum dose limits compared to adults, reflecting increased long-term cardiac risk. Older adults may also be considered a high-risk group requiring careful assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adriamycin (Doxorubicin) has officially documented interactions that can alter drug exposure or increase the risk of specific toxicities, according to government regulatory information.

Pharmacokinetic and Exposure Interactions

Doxorubicin is a major substrate for the P-glycoprotein (P-gp) transporter and is metabolized by the CYP3A4 and CYP2D6 enzymes. Co-administration with inhibitors of these enzymes or P-gp will increase the plasma concentration of Doxorubicin, while co-administration with inducers (including the herbal product St. John's Wort) may decrease the drug's concentration. Concomitant use with these agents must be avoided. Furthermore, in patients with severe hepatic impairment, clearance is reduced, which increases systemic exposure and risk for toxicity.

Pharmacodynamic and Administration Constraints

Co-administration with other cardiotoxic drugs (e.g., other anthracyclines) or prior radiotherapy to the chest area increases the risk of cardiac toxicity. The combination of Doxorubicin and Trastuzumab is contraindicated due to this heightened cardiac risk. Administration requires strict timing rules: Doxorubicin must be given prior to Paclitaxel to prevent increased Doxorubicin exposure, and it must not be admixed with Heparin or Fluorouracil due to physical incompatibility.

Mechanism of Action

The mechanism of Adriamycin (Doxorubicin) is a multifactorial cytotoxic action that fundamentally leads to the induction of cell death in rapidly dividing cells.

This mechanism is initiated by the drug acting on three separate targets within the cell nucleus. First, it causes DNA intercalation, physically inserting itself between the DNA double helix base pairs, thereby impeding the function of DNA and RNA polymerases. Second, it functions as a Topoisomerase II poison, stabilizing the enzyme-DNA complex after the strands have been cut. This enzymatic poisoning prevents resealing, resulting in the formation of overwhelming, severe double-strand DNA breaks (DSBs).

An additional multi-target mechanism involves redox cycling, where the drug's chemical structure generates highly reactive species, primarily the hydroxyl free radical ( OH^cdot). This cascade causes widespread oxidative damage to cellular structures. The combined genetic and chemical stress forces the cell into apoptosis (programmed cell death), which is the core physiological mechanism behind the drug's final cytotoxic effect.

Dosage and Administration Information

How to Use Adriamycin

The administration of Adriamycin (Doxorubicin) is governed by precise, standardized protocols for use in clinical practice. The primary and systemic method is the Intravenous (IV) route, where the medicine is delivered directly into a large vein or central catheter, necessitating administration in a specialist hospital or clinic setting. A separate, localized method, Intravesical instillation, is officially approved for application within the bladder.

Dosing is strictly calculated based on the patient’s Body Surface Area (BSA) and is expressed in milligrams per square meter (mg/m^2). The typical single-agent dose falls within the range of 60 mg/m^2 to 75 mg/m^2, administered in defined treatment cycles, most commonly once every 21 days. A critical instruction is the Maximum Cumulative Dose limit, which generally must not exceed 550 mg/m^2 over a patient's lifetime. This limit is often lower, le 450 mg/m^2, for patients who are older or who have received prior chest radiation.

Preparation of the solution requires adherence to specific conditions: the drug must be diluted in designated fluids like 0.9% Sodium Chloride or 5% Dextrose and must be protected from light throughout the entire preparation and infusion process. Furthermore, dose adjustments are mandatory for patients with hepatic impairment (poor liver function), with prescribed reductions linked directly to serum bilirubin levels, ensuring the regimen adheres to the instructions for physiological constraints. The final step of the procedure involves slow IV administration over a specified time, such as a 3 to 10-minute bolus.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adriamycin (Doxorubicin)

This overview describes the scope of clinical research conducted for Adriamycin (Doxorubicin), detailing the types of studies available, the outcomes they measured, and where research remains uncertain. This information is purely descriptive and does not constitute medical advice or treatment recommendations.

Evidence for Use in Solid Tumors (Breast Cancer and Sarcomas)

Research exploring Doxorubicin’s role in treating solid tumors includes large-scale Randomized Phase III Trials and comprehensive Meta-analyses that combine data from many individual studies. These study types were utilized in the research. The medication was evaluated in research for both early-stage disease, such as breast cancer, and for advanced or metastatic disease, including various types of soft tissue sarcoma.

Studies monitored important long-term outcomes, such as Overall Survival (OS) and Disease-Free Survival (DFS), which are measured time points in clinical trials. Because Doxorubicin is generally used as one part of a multi-drug regimen, studies explored how specific combinations of treatments compared against other protocols based on measured outcomes. Clarifying the contribution of the single agent is challenging, as the evidence primarily stems from studies of complex, multi-drug combination regimens.

Evidence for Use in Hematologic Cancers (Leukemias and Lymphomas)

Research evaluated Doxorubicin in blood cancers, including Acute Leukemias (ALL/AML) and Hodgkin/Non-Hodgkin Lymphomas, using Randomized Controlled Trials and long-term Observational Cohort Studies. These studies monitor outcomes related to systemic or functional imbalance, such as the achievement of a Complete Remission (CR) and Event-Free Survival (EFS), which is a measured time point that relates to the occurrence of a specific event.

Studies explored Doxorubicin as a frequently used part of multi-agent chemotherapy protocols. Research highlights changes measured during the study period related to remission status. Evidence quality varies across studies, particularly for older data included in meta-analyses.

Long-Term Studies and Follow-Up Data

Studies monitored the long-term status of patients who were evaluated in trials of Doxorubicin, with some follow-up periods extending up to 15 years or more. This long-term research contributes to understanding extended outcomes in diseases like Hodgkin Lymphoma. However, long-term effects are not fully established across all indications, and the specific long-term impact of Doxorubicin versus the combination remains challenging to separate in the available research.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Adriamycin (FAQ)

Q: What types of cancers is Adriamycin typically used for?

A: Official regulatory documents indicate that Adriamycin is used for the systemic treatment of a variety of malignancies. This includes certain types of breast cancer, acute leukemias, lymphomas (both Hodgkin's and non-Hodgkin's), and soft tissue and bone sarcomas. It is often used as part of a multi-drug chemotherapy regimen.

Q: Does Adriamycin change the color of your urine?

A: Yes, official patient counseling information states that Adriamycin can cause the urine to temporarily turn a reddish color. This is an expected effect of the medication, typically lasting 1 to 2 days after administration. Official information notes this discoloration is usually due to the drug and is not blood.

Q: What are the most common immediate side effects during the Adriamycin infusion?

A: Some common reactions have been reported during or shortly after the intravenous infusion. These can include pain or redness at the injection site, red streaks along the injected vein, flushing, headache, and chills. These effects are typically managed by the healthcare team during administration.

Q: Is it normal to feel very fatigued for several days after an Adriamycin treatment?

A: Yes, regulatory product information lists fatigue (asthenia or general weakness) among the most common adverse reactions reported by patients during clinical trials. It is a frequent side effect observed after a treatment dose.

Q: How long after the infusion does hair loss usually start with Adriamycin?

A: Hair loss, or alopecia, is a nearly universal side effect of this treatment. While the timing is variable among individuals, hair loss is typically observed beginning within the first few weeks of therapy, often becoming noticeable after one or two months.

Q: Can Adriamycin treatment cause long-term heart problems?

A: Yes, a major risk highlighted in official warnings is cardiotoxicity (heart damage). This can lead to serious, sometimes irreversible, conditions like chronic cardiomyopathy or congestive heart failure. The risk of these serious long-term effects is closely monitored and is generally related to the total cumulative dose administered over a patient’s lifetime.

Q: How often is Adriamycin usually given in a treatment cycle?

A: According to the official prescribing information, Adriamycin is administered intravenously in defined treatment cycles. While specific schedules vary based on the cancer type and protocol, it is most commonly given once every 21 days.

Q: Is it safe to get a flu shot while undergoing Adriamycin treatment?

A: Because Adriamycin can cause myelosuppression (a severe lowering of blood cell counts that weakens the immune system), regulatory information advises caution or avoidance of live vaccines in patients receiving treatment.

Q: Does Adriamycin treatment weaken your immune system?

A: Yes, a dose-limiting toxicity is myelosuppression, or bone marrow suppression. This effect lowers the number of white blood cells (neutropenia), which weakens the body's immune defenses and increases the risk of infection.

Q: How long does Adriamycin stay in your system after the last dose?

A: Regulatory documents describe a complex elimination process. The drug is quickly distributed throughout the body, but its removal from the bloodstream is slow. The parent drug's half-life (the time it takes for half the drug to be eliminated) typically ranges from 1.5 to 30 hours, with its active metabolite sometimes taking longer to clear.

Q: Can Adriamycin cause mouth sores, and how can they be managed?

A: Yes, mucositis or stomatitis (inflammation and sores in the mouth and gut lining) is listed as a very common adverse effect. Official product information notes that management of these symptoms is typically handled with supportive care measures to minimize the discomfort.

Q: What kind of monitoring is done during Adriamycin therapy?

A: Official labeling requires strict monitoring throughout therapy to ensure patient safety. This includes regular assessment of heart function (Left Ventricular Ejection Fraction or LVEF), frequent checks of complete blood counts, and monitoring of liver function tests.

Q: Are there different brand names for the drug Adriamycin?

A: Yes, the active substance is Doxorubicin. While Adriamycin is a well-known trade name for the standard formulation, the drug is also available under other brand names. This includes specialized liposomal formulations, such as Doxil or Caelyx.

Q: Is Adriamycin used in both early and advanced-stage cancers?

A: According to official indications and studies, Adriamycin has authorized uses for treating malignancies at various stages. This includes its use in adjuvant therapy (for early-stage disease following surgery) and for treating advanced or metastatic disease that has spread to other parts of the body.

Q: Can Adriamycin affect fertility in men and women?

A: Official prescribing information warns that Doxorubicin may cause infertility in both sexes. This can manifest as low sperm counts (oligospermia) in males, and premature menopause or the absence of menstruation (amenorrhea) in females. These effects may be temporary or permanent.

Q: Can Adriamycin be used to treat non-cancer conditions?

A: The authorized indications for Doxorubicin, as documented in regulatory sources, are strictly limited to the treatment of various malignancies (cancers). The medication is not officially labeled or approved for use in treating non-cancer conditions.

Q: Does Adriamycin make you more sensitive to the sun?

A: Yes, photosensitivity (an increased sensitivity to sunlight that can lead to severe sunburn or rashes) is listed in regulatory documents as a potential adverse reaction to this medication.

Q: Can Adriamycin treatment cause pain or redness at the injection site?

A: Official warnings specify that severe local tissue necrosis (tissue damage) will occur if the drug leaks out of the vein, a process called extravasation. The official label specifically warns about red streaks along the injected vein and emphasizes the potential for tissue damage at the administration site.

Q: How soon after stopping Adriamycin can hair start to grow back?

A: Official product information states that the hair loss (alopecia) is typically reversible upon the cessation of therapy. However, the exact time frame for hair regrowth varies widely among individuals and is not specified in regulatory documents.

Q: What is the typical duration of an Adriamycin treatment regimen?

A: The overall length of an Adriamycin treatment regimen is highly dependent on the patient's specific cancer type and the combination of drugs used. Treatment may continue for a specified number of cycles, or until the maximum cumulative lifetime dose is reached to manage cardiac risk.

Q: Is it possible to receive Adriamycin without experiencing nausea?

A: Acute nausea and vomiting are frequent side effects that can sometimes be severe. However, official information notes that these effects can be significantly alleviated by using effective antiemetic (anti-nausea) therapy, suggesting the severity and occurrence of nausea may be significantly reduced.

Q: Is it normal to have a metallic taste in the mouth after an infusion?

A: While the official regulatory label for the injection does not specifically list 'metallic taste,' it does include other gastrointestinal adverse effects like anorexia and stomatitis (mouth inflammation), which are commonly associated with taste changes during chemotherapy.

Q: What percentage of people experience cardiotoxicity from Adriamycin?

A: Official warnings emphasize that the risk of myocardial damage and congestive heart failure is directly proportional to the total cumulative dose of the drug administered. The risk increases significantly as the lifetime dose exceeds the generally accepted limits, which is why the dose is closely monitored and limited.

How should Adriamycin be stored and disposed of?

How to Store and Dispose of Adriamycin?

The storage and disposal of Adriamycin (doxorubicin hydrochloride) must follow strict regulatory guidelines, as it is classified as a cytotoxic and hazardous drug.

Official Storage Conditions

Requirement	Specification
Temperature	Store refrigerated, between 2°C and 8°C (36°F and 46°F).
Protection	Keep vials in the original carton to protect from light.
Child Safety	Must be kept out of the sight and reach of children.
Stability Note	If solution gels in the refrigerator, it requires placement at room temperature (15°C to 30°C) for 2 to 4 hours to re-liquefy prior to use.

Disposal Requirements

The product and all associated materials are recognized as hazardous waste and must be handled and disposed of consistent with local regulatory and institutional guidelines for cytotoxic drugs. The unused portion of any single-dose vial must be discarded, not saved for later use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.